Presentation is loading. Please wait.

Presentation is loading. Please wait.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

Published byMavis Gilbert Modified over 5 years ago

Similar presentations

Presentation on theme: "The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference."— Presentation transcript:

1 The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference between the two sets of data points being statistically significant (P<0.05). ESMO, European Society for Medical Oncology; NICE, National Institute for Health and Care Excellence; SIGN, Scottish Intercollegiate Guidelines Network. The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference between the two sets of data points being statistically significant (P<0.05). ESMO, European Society for Medical Oncology; NICE, National Institute for Health and Care Excellence; SIGN, Scottish Intercollegiate Guidelines Network. Elena Pallari et al. ESMO Open 2018;3:e000258 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference."

Similar presentations

FACULTY OF MEDICINE The use of Cochrane breast cancer reviews by guideline developers and Cochrane (public) users Cochrane Breast Cancer Group, NHMRC Clinical.

FACULTY OF MEDICINE The use of Cochrane breast cancer reviews by guideline developers and Cochrane (public) users Cochrane Breast Cancer Group, NHMRC Clinical.
The contribution of research papers by cancer application site on the two sets of cancer clinical practice guidelines, in comparison with the corresponding.

The contribution of research papers by cancer application site on the two sets of cancer clinical practice guidelines, in comparison with the corresponding.
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart summarising the process for the identification of eligible studies.

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart summarising the process for the identification of eligible studies.
For 24 countries with more than 20 citations, this figure compares contributions to ESMO and the UK cancer CPGs. Solid line of identity indicates equal.

For 24 countries with more than 20 citations, this figure compares contributions to ESMO and the UK cancer CPGs. Solid line of identity indicates equal.
Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.
Clinical algorithm of diagnosis and treatment of bone metastasis guideline. Clinical algorithm of diagnosis and treatment of bone metastasis guideline.

Clinical algorithm of diagnosis and treatment of bone metastasis guideline. Clinical algorithm of diagnosis and treatment of bone metastasis guideline.
Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.

Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
Progesterone receptor nuclear morphology patterns in breast cancer.

Progesterone receptor nuclear morphology patterns in breast cancer.
Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.
Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.
Flow chart of the used methodology adapted from Moher et al

Flow chart of the used methodology adapted from Moher et al
The decision tree with the two alternatives.

The decision tree with the two alternatives.
Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.

Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.
PRISMA study flow diagram

PRISMA study flow diagram
Kaplan-Meier curves for overall survival (OS) probability.

Kaplan-Meier curves for overall survival (OS) probability.

Similar presentations

Ads by Google